BioPharma Resources

Drug Trial Radar · NCT02610348

Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

Persistence of Anti-Hep B Antibodies at 12 to 18 Months of Age in Children Having Received Hep B Vaccine at Birth and a DTaP-IPV-HB-Hib Hexavalent Vaccine (Hexaxim® or Infanrix Hexa®) Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

Last checked: Nov 19, 2026Latest source record: Mar 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

122

Actual

Start

Nov 2015

Primary completion

Dec 2015

Study completion Mar 2016

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 12 months, up to 18 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.

Conditions

  • Hepatitis B

Interventions

  • DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccinesBiological

    Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study

  • DTaP-HB-IPV and Pneumococcal polysaccharide vaccinesBiological

    Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Levels of anti-Hepatitis B antibody concentrations in subject that received Hexaxim® or Infanrix® hexa vaccine in a previous studyTime frame: Day 0

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Bangkok, Thailand

  • Site not named

    Khon Kaen, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.